---
schema_version: "secwatch.filing_event.v1"
accession: "0001411690-23-000080"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:02:19.454450+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bionano Q3 revenue $9.3M (+29% YoY); $80M convertible notes completed; $33M cost savings plan

## Summary
- Q3 revenue $9.3M, +29% YoY; GAAP gross margin 30% vs 25% YoY; non-GAAP operating expense $31.8M.
- Completed $80M convertible notes offering (Oct 13), extending cash runway; cash & securities $63.6M.
- Cost reduction initiatives expected to save ~$33M annually starting 2024; reiterated FY2023 rev guidance $35-$38M.
- Saphyr installed base 301 (+39% YoY); flowcells sold 6,176 (+55% YoY); OGM publications up 61% YoY.
- Appointed Gülsen Kama as CFO effective Sept 11, 2023.

## SEC filing metadata
- accession: 0001411690-23-000080
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000141169023000080/0001411690-23-000080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000141169023000080/bngo-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411690-23-000080
- JSON: https://secwatch.observer/filing/0001411690-23-000080.json
- Plain text: https://secwatch.observer/filing/0001411690-23-000080.txt

## Key facts
- Earnings Releases
  Bionano Genomics, Inc. reported third quarter ended September 30, 2023 results: revenue $9.3 million. Guidance reaffirmed.
  - Period: third quarter ended September 30, 2023
  - Revenue: $9.3 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Bionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress • Q3 2023 revenue was $9.3 million, which represents a 29% increase over Q3 2022 • Installed base of Saphyr ® systems totaled 301 as of September 30, 2023, which represents a 39% increase over the number of systems installed as of September 30, 2022 • Sold 6,176 nanochannel array flowcells in Q3 2023, which represents a 55% increase over the number of flowcells sold in Q3 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411690/000141169023000080/0001411690-23-000080-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.